Restenosis--an open file
Related Experiment Video
Updated: Nov 5, 2026
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
M Gottsauner-Wolf1, D J Moliterno, A M Lincoff
1Department of Cardiology, Cleveland Clinic Foundation, OH 44195, USA.
Insights
Percutaneous coronary angioplasty restenosis remains a challenge, affecting one-third to one-half of patients. Novel therapies like glycoprotein IIb/IIIa inhibitors and stents show promise in reducing restenosis recurrence.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Biomedical Engineering
Background:
- Restenosis, the re-narrowing of a treated coronary artery segment, is a primary limitation of percutaneous coronary angioplasty (PCA).
- Despite technological advancements, restenosis affects 33-50% of patients within six months, driven by plaque persistence, thrombus formation, and cellular proliferation.
- Understanding the biological mechanisms of restenosis is crucial for developing effective prevention strategies.
Purpose of the Study:
- To review the mechanisms underlying restenosis following percutaneous coronary angioplasty.
- To evaluate the efficacy of emerging pharmacologic and mechanical therapies in preventing restenosis recurrence.
- To discuss the potential of future treatments for complete prevention of stenosis recurrence.
Main Methods:
- Review of animal models to elucidate restenosis mechanisms.
- Analysis of clinical trial data for pharmacologic agents and mechanical devices.
- Evaluation of glycoprotein IIb/IIIa receptor antagonists and intracoronary metallic stents.
Main Results:
- Animal models have been instrumental in understanding restenosis biology and testing interventions.
- Glycoprotein IIb/IIIa inhibitors and intracoronary stents have emerged as promising therapies.
- Both strategies, when used independently, demonstrate a 20-30% reduction in clinical restenosis at 6-month follow-up.
Conclusions:
- Current therapeutic strategies, including glycoprotein IIb/IIIa inhibitors and intracoronary stents, significantly reduce restenosis rates.
- Continued research into the biological processes of restenosis and refinement of treatments hold promise for preventing recurrence.
- The ultimate goal is to achieve complete prevention of coronary stenosis recurrence after angioplasty.
Abstract:
The main procedural drawback to percutaneous coronary angioplasty is restenosis of the treated site within 6 months. Despite advances in equipment, technique, and adjunctive therapies, restenosis has occurred in approximately one-third to one-half of all patients. The biology of restenosis can be divided into plaque persistence and recoil, thrombus formation and transformation, and cellular proliferation and vascular remodeling. Animal models of restenosis have helped to elucidate these mechanisms of restenosis and provide a means to test pharmacologic and mechanical strategies to reduce stenosis recurrence. While numerous agents have been tested in animal models, until recently none has translated into benefit in large-scale clinical trials. Two therapeutic "hopefuls" which have recently emerged in clinical practice are the potent platelet inhibitors, glycoprotein IIb/IIIa receptor antagonists, and intracoronary metallic stents. The IIb/IIIa receptor antagonists target thrombus formation at the angioplasty site, thereby minimizing abrupt vessel closure acutely and neointimal growth chronically, while intracoronary stents safely produce a large coronary arterial lumen acutely and prevent vessel recoil. Separately, these therapeutic strategies have been shown to reduce clinical restenosis 20-30% at 6-month follow-up. With these encouraging results, the future will certainly provide more pharmacologic and mechanical therapies targeting restenosis. With increased understanding of the restenotic process and continued refinement of effective treatments, it may be possible one day to prevent stenosis recurrence.
Related Concept Videos
01:26Aneurysm III: Interprofessional Care
01:24Healing II: Complications
01:26Residual Stresses